22.09.2024, 1292 Zeichen

Valneva: Valneva, a specialty vaccine company, announced that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to potentially expand the use of its chikungunya vaccine, IXCHIQ^®, to adolescents aged 12 to 17 years in Europe and Canada. The Canadian label extension application also includes two-year antibody persistence data, which is a key differentiator for IXCHIQ^® that was already included in the initial EMA filing. Valneva expects to submit data to the U.S. Food and Drug Administration (FDA) this year to also support potential label extensions in the U.S.
Valneva: weekly performance: -17.94%

Marinomed: Marinomed Biotech AG has resolved to increase the Company's share capital by EUR 154,053. The issue price per new share is EUR 5, so that the total issue price amounts to EUR 770,265. All 154,053 new shares have been subscribed at these issue terms and conditions by a total of eleven investors, including members of the Supervisory and Management Boards. The Company is continuing to negotiate with another investor regarding a possible second capital increase of a further 154,053 new shares.
Marinomed Biotech: weekly performance: -9.39%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (18/09/2024)

Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice 113/365: Was StudentInnen der Wirtschaftsuni Wien zur Wiener Börse sagen

Bildnachweis

Aktien auf dem Radar:Palfinger, CPI Europe AG, Frequentis, RHI Magnesita, Rosenbauer, Kapsch TrafficCom, VIG, OMV, Uniqa, voestalpine, Zumtobel, Andritz, AT&S, Lenzing, Bawag, DO&CO, Erste Group, RBI, Wolford, Agrana, Oberbank AG Stamm, Warimpex, Polytec Group, Amag, Flughafen Wien, Österreichische Post, Telekom Austria, ATX.

---